Reciprocal interactions between bile acids and gut microbiota in human liver diseases

Hepatology Research

Volumn 48, Issue 1, 2018, Pages 15-27

  Ikegami, Tadashi ^a   Honda, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

bile acids; dysbiosis; farnesoid X receptor (FXR); gut microbiota

Indexed keywords

ANTIBIOTIC AGENT; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLIC AMP; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 5; TEMPOL;

AUTOIMMUNE LIVER DISEASE; BACTERIAL MEMBRANE; BARIATRIC SURGERY; BILE ACID METABOLISM; BINDING AFFINITY; CONJUGATION; DISEASE ASSOCIATION; DISEASE COURSE; EPIMERIZATION; HUMAN; HYDROGENATION; HYDROXYLATION; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER DISEASE; MACROMOLECULE; MOLECULAR INTERACTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 85040107521     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.13001     Document Type: Review

References (126)

1. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241–259.
2. Vlahcevic ZR, Stravitz RT, Heuman DM, Hylemon PB, Pandak WM. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 1997; 113: 1949–1957.
3. Duane WC, Javitt NB. 27-Hydroxycholesterol: production rates in normal human subjects. J Lipid Res 1999; 40: 1194–1199.
4. Liu HX, Keane R, Sheng L, Wan YJ. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol 2015; 63: 1502–1510.
5. Jansen PL, Ghallab A, Vartak N et al. The ascending pathophysiology of cholestatic liver disease. Hepatology 2017; 65: 722–738.
6. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009; 15: 1677–1689.
7. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543–553.
8. Makishima M, Lu TT, Xie W et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313–1316.
9. Staudinger JL, Goodwin B, Jones SA et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98: 3369–3374.
10. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435–9440.
11. Nagahashi M, Yuza K, Hirose Y et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J Lipid Res 2016; 57: 1636–1643.
12. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S et al. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS One 2010; 5: e9689.
13. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147–191.
14. Lee JM, Wagner M, Xiao R et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 2014; 516: 112–115.
15. Seok S, Fu T, Choi SE et al. Transcriptional regulation of autophagy by an FXR–CREB axis. Nature 2014; 516: 108–111.
16. Watanabe M, Houten SM, Wang L et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408–1418.
17. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 2015; 17: 500.
18. Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B 2015; 5: 129–134.
19. Jahn D, Rau M, Hermanns HM, Geier A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev 2015; 26: 625–635.
20. Fuchs CD, Traussnigg SA, Trauner M. Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease. Semin Liver Dis 2016; 36: 69–86.
21. Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 2015; 72: 1631–1650.
22. Cariou B, Chetiveaux M, Zair Y et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab (Lond) 2011; 8: 48.
23. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011; 54: 1263–1272.
24. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167–177.
25. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484–489.
26. Broeders EP, Nascimento EB, Havekes B et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 2015; 22: 418–426.
27. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157.
28. Alarcon C, Wicksteed B, Rhodes CJ. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006; 49: 2920–2929.
29. Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365–1368.
30. Lepage P, Leclerc MC, Joossens M et al. A metagenomic insight into our gut's microbiome. Gut 2013; 62: 146–158.
31. Fukuda S, Toh H, Hase K et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543–547.
32. Collins MD, Lawson PA, Willems A et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 1994; 44: 812–826.
33. Ohno H. Impact of commensal microbiota on the host pathophysiology: focusing on immunity and inflammation. Semin Immunopathol 2015; 37: 1–3.
34. Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55–60.
35. Karlsson FH, Fak F, Nookaew I et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3: 1245.
36. Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575–1584.
37. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480–484.
38. Fujimura KE, Sitarik AR, Havstad S et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med 2016; 22: 1187–1191.
39. Hsiao EY, McBride SW, Hsien S et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013; 155: 1451–1463.
40. Miyake S, Kim S, Suda W et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS One 2015; 10: e0137429.
41. Hasegawa S, Goto S, Tsuji H et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLoS One 2015; 10: e0142164.
42. Mouzaki M, Comelli EM, Arendt BM et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58: 120–127.
43. Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63: 764–775.
44. Yoshimoto S, Loo TM, Atarashi K et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97–101.
45. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015; 37: 47–55.
46. Andoh A, Tsujikawa T, Sasaki M et al. Faecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Aliment Pharmacol Ther 2009; 29: 75–82.
47. Joossens M, Huys G, Cnockaert M et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631–637.
48. Nemoto H, Kataoka K, Ishikawa H et al. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci 2012; 57: 2955–2964.
49. Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149: 110–8.e4.
50. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24–33.
51. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016; 375: 2369–2379.
52. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011; 3: 858–876.
53. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242–249.
54. Joyce SA, Gahan CG. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis 2017; 35: 169–177.
55. Joyce SA, MacSharry J, Casey PG et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 2014; 111: 7421–7426.
56. Joyce SA, Shanahan F, Hill C, Gahan CG. Bacterial bile salt hydrolase in host metabolism: potential for influencing gastrointestinal microbe–host crosstalk. Gut Microbes 2014; 5: 669–674.
57. Coleman JP, Hudson LL. Cloning and characterization of a conjugated bile acid hydrolase gene from Clostridium perfringens. Appl Environ Microbiol 1995; 61: 2514–2520.
58. Christiaens H, Leer RJ, Pouwels PH, Verstraete W. Cloning and expression of a conjugated bile acid hydrolase gene from Lactobacillus plantarum by using a direct plate assay. Appl Environ Microbiol 1992; 58: 3792–3798.
59. Elkins CA, Savage DC. Identification of genes encoding conjugated bile salt hydrolase and transport in Lactobacillus johnsonii 100-100. J Bacteriol 1998; 180: 4344–4349.
60. Tanaka H, Hashiba H, Kok J, Mierau I. Bile salt hydrolase of Bifidobacterium longum –biochemical and genetic characterization. Appl Environ Microbiol 2000; 66: 2502–2512.
61. Gopal-Srivastava R, Hylemon PB. Purification and characterization of bile salt hydrolase from Clostridium perfringens. J Lipid Res 1988; 29: 1079–1085.
62. Stellwag EJ, Hylemon PB. 7α-Dehydroxylation of cholic acid and chenodeoxycholic acid by Clostridium leptum. J Lipid Res 1979; 20: 325–333.
63. Kitahara M, Takamine F, Imamura T, Benno Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7α-dehydroxylating activity. Int J Syst Evol Microbiol 2001; 51: 39–44.
64. Kitahara M, Takamine F, Imamura T, Benno Y. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7α-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2000; 50(Pt 3): 971–978.
65. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 2013; 4: 382–387.
66. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332–338.
67. Islam KB, Fukiya S, Hagio M et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 1773–1781.
68. Yokota A, Fukiya S, Islam KB et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes 2012; 3: 455–459.
69. Watanabe M, Fukiya S, Yokota A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res 2017; 58: 1143–1152.
70. Murakami M, Iwamoto J, Miyazaki T et al. Detection of gut dysbiosis due to reduced Clostridium subcluster XIVa by based on the serum bile acid profile. Inflamm Bowel Dis (in press).
71. Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389–97.e10.
72. Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 2016; 15: 249–274.
73. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013; 86: 1517–1524.
74. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55–67.
75. Quigley EM, Monsour HP. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis 2015; 35: 262–269.
76. Boursier J, Diehl AM. Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis 2016; 20: 263–275.
77. Kohli R, Myronovych A, Tan BK et al. Bile acid signaling: mechanism for bariatric surgery, cure for NASH? Dig Dis 2015; 33: 440–446.
78. Bower G, Athanasiou T, Isla AM et al. Bariatric surgery and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27: 755–768.
79. Ferslew BC, Xie G, Johnston CK et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015; 60: 3318–3328.
80. Aranha MM, Cortez-Pinto H, Costa A et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008; 20: 519–525.
81. Kalhan SC, Guo L, Edmison J et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404–413.
82. Mouzaki M, Wang AY, Bandsma R et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One 2016; 11: e0151829.
83. Jiao N, Baker SS, Chapa-Rodriguez A et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 2017; gutjnl-2017-314307.
84. Le Roy T, Llopis M, Lepage P et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62: 1787–1794.
85. Henao-Mejia J, Elinav E, Jin C et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179–185.
86. De Minicis S, Rychlicki C, Agostinelli L et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014; 59: 1738–1749.
87. Loomba R, Seguritan V, Li W et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017; 25: 1054–62.e5.
88. Tanaka A, Gershwin ME. Finding the cure for primary biliary cholangitis – still waiting. Liver Int 2017; 37: 500–502.
89. Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid. Semin Liver Dis 2016; 36: 15–26.
90. Williamson KD, Chapman RW. New therapeutic strategies for primary sclerosing cholangitis. Semin Liver Dis 2016; 36: 5–14.
91. Goode EC, Rushbrook SM. A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis 2016; 7: 68–85.
92. Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 2017; 16: 885–896.
93. Hisamoto S, Shimoda S, Harada K et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J Autoimmun 2016; 75: 150–160.
94. Bleier JI, Katz SC, Chaudhry UI et al. Biliary obstruction selectively expands and activates liver myeloid dendritic cells. J Immunol 2006; 176: 7189–7195.
95. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217–1227.
96. Modica S, Petruzzelli M, Bellafante E et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355–365. e1-4.
97. Keitel V, Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012; 36: 412–419.
98. Kevans D, Tyler AD, Holm K et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 2016; 10: 330–337.
99. Torres J, Bao X, Goel A et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016; 43: 790–801.
100. Kummen M, Holm K, Anmarkrud JA et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66: 611–619.
101. Sabino J, Vieira-Silva S, Machiels K et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65: 1681–1689.
102. Ruhlemann MC, Heinsen FA, Zenouzi R, Lieb W, Franke A, Schramm C. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 2017; 66: 753–754.
103. Quraishi MN, Sergeant M, Kay G et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 2017; 66: 386–388.
104. Lv LX, Fang DQ, Shi D et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 2016; 18: 2272–2286.
105. Tang R, Wei Y, Li Y et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2017; gutjnl-2016-313332.
106. Chen Y, Yang F, Lu H et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562–572.
107. Kakiyama G, Pandak WM, Gillevet PM et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949–955.
108. Scarpellini E, Valenza V, Gabrielli M et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105: 323–327.
109. Bajaj JS, Hylemon PB, Ridlon JM et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303: G675–G685.
110. Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940–947.
111. Qin N, Yang F, Li A et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513: 59–64.
112. Watanabe M, Horai Y, Houten SM et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011; 286: 26913–26920.
113. Pellicciari R, Fiorucci S, Camaioni E et al. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569–3572.
114. Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375: 631–643.
115. Jhaveri MA, Kowdley KV. New developments in the treatment of primary biliary cholangitis – role of obeticholic acid. Ther Clin Risk Manag 2017; 13: 1053–1060.
116. Mudaliar S, Henry RR, Sanyal AJ et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574–82.e1.
117. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956–965.
118. Ubeda M, Lario M, Munoz L et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016; 64: 1049–1057.
119. Zhou M, Yang H, Learned RM, Tian H, Ling L. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017; 8: 15433.
120. Prawitt J, Abdelkarim M, Stroeve JH et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861–1871.
121. Jiang C, Xie C, Lv Y et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6: 10166.
122. Jiang C, Xie C, Li F et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125: 386–402.
123. Sayin SI, Wahlstrom A, Felin J et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225–235.
124. Mueller M, Thorell A, Claudel T et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 2015; 62: 1398–1404.
125. Gonzalez FJ, Jiang C, Bisson WH, Patterson AD. Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity. J Hepatol 2015; 62: 1234–1236.
126. Sharma R, Prichard D, Majer F et al. Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. J Med Chem 2011; 54: 122–130.